Imkeldi — CareFirst (Caremark)
Myeloid/Lymphoid Neoplasms with Eosinophilia
Preferred products
- Gleevec
- imatinib mesylate
Initial criteria
- Diagnosis of myeloid and/or lymphoid neoplasms with eosinophilia and ABL1, FIP1L1::PDGFRA, or PDGFRB rearrangement in chronic or blast phase
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months